Items tagged with Scientific research

PLOS Medicine Special Collection on Advances in Clinical Trial Design for Development of New Treatments for TB (post)

06 March 2020 | GENEVA -- A Special Collection on Advances in Clinical Trial Design for Development of New Treatments for Tuberculosis has been released by PLOS Medicine. This Special Collection, that is now complete with the publication of its last paper, contains a series of articles that articulate the essential new steps in clinical research that will pave the way for the development of future optimal treatment for all forms of tuberculosis. The Collection has been sponsored by the World Health Organization (WHO) and the French National Research Institute for Sustainable Development (IRD-France), and coordinated by Dr Christian Lienhardt, Research Director at IRD-France and Dr Payam Nahid, Professor at University of California, San Francisco, USA

Study: Cough that spreads TB has pain-linked trigger (post)

Tuberculosis is distinguished primarily by the persistent cough that serves to spread the disease. Stopping whatever triggers that cough could greatly reduce the transmission of the disease, which annually kills more than 1.3 million people worldwide.

Why the new WHO COVID-19 therapeutic trial is a step in the right direction (post)

Finding out which medicines work and which ones do not work can be a tricky business – especially if you are under severe time pressure. The ideal is to compare different options in large randomised controlled trials (RCTs), preferably trials where neither the study participants or healthcare workers know who is getting which treatment.

Latest TB research publications (post)

Can a century-old TB vaccine steel the immune system against the new coronavirus? (post)

Researchers in four countries will soon start a clinical trial of an unorthodox approach to the new coronavirus. They will test whether a century-old vaccine against tuberculosis (TB), a bacterial disease, can rev up the human immune system in a broad way, allowing it to better fight the virus that causes coronavirus disease 2019 and, perhaps, prevent infection with it altogether. The studies will be done in physicians and nurses, who are at higher risk of becoming infected with the respiratory disease than the general population, and in the elderly, who are at higher risk of serious illness if they become infected.

Pulmonary TB enhances HIV-1 antibody responses (post)

Active infection with Mycobacterium tuberculosis (TB) enhances anti-HIV-1 antibody response, which may then lead to the emergence of broadly neutralizing antibodies (bnAbs) that target conserved envelope domains.

Researcher discovers giant cavity in key TB molecule (post)

The giant cavity, in a protein that transports nutrients across the cell membrane, is unlike anything researchers have seen before.

Latest TB research publications (post)

Blocking the iron transport could stop TB (post)

The bacteria that cause tuberculosis need iron to survive. Researchers at the University of Zurich have now solved the first detailed structure of the transport protein responsible for the iron supply. When the iron transport into the bacteria is inhibited, the pathogen can no longer grow. This opens novel ways to develop targeted tuberculosis drugs.

GHIT Fund announces new investments to develop drugs, vaccines, diagnostics for malaria, TB, NTDs (post)

The Global Health Innovative Technology (GHIT) Fund announced a total of 3.29 billion yen (US$30 million) to invest in 11 partnerships to develop new lifesaving drugs, vaccines and diagnostics for malaria, TB, Chagas disease, leishmaniasis, lymphatic filariasis, onchocerciasis, and mycetoma. This includes five new projects and six that will receive continued funding.